scout
|Videos|January 11, 2017

Maximizing the Clinical Benefit of Crizitonib in NSCLC

Nicolas Girard, MD, discusses how to maximize the clinical benefit of crizitonib (Xalkori) in non-small cell lung cancer (NSCLC). 

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME